OTCPK:RFCS

Stock Analysis Report

Executive Summary

Refocus Group, Inc., a medical device company, engages in the research and development of treatments for human vision disorders, primarily for presbyopia.


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has Refocus Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RFCS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

18.9%

RFCS

11.3%

US Medical Equipment

5.3%

US Market


1 Year Return

0%

RFCS

-4.5%

US Medical Equipment

-10.7%

US Market

Return vs Industry: RFCS exceeded the US Medical Equipment industry which returned -4.5% over the past year.

Return vs Market: RFCS exceeded the US Market which returned -10.7% over the past year.


Shareholder returns

RFCSIndustryMarket
7 Day18.9%11.3%5.3%
30 Day13.3%-8.5%-13.6%
90 Day37.1%-15.6%-19.8%
1 Year0%0%-3.8%-4.5%-8.9%-10.7%
3 Year-64.6%-64.6%47.0%43.0%15.5%8.0%
5 Year-15.0%-15.0%78.8%60.2%35.2%20.4%

Price Volatility Vs. Market

How volatile is Refocus Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Refocus Group undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Refocus Group is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Refocus Group has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of RFCS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Refocus Group regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Refocus Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Refocus Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of RFCS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Refocus Group's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Refocus Group performed over the past 5 years?

13.1%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Refocus Group has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Refocus Group's financial position?


In this section we usually analyse Refocus Group's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Refocus Group has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of RFCS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Refocus Group's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Refocus Group's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RFCS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate RFCS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RFCS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RFCS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RFCS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.4yrs

Average management tenure


CEO

Mike Judy (58yo)

6.5s

Tenure

Mr. J. Michael Judy, also known as Mike, has been the Chief Executive Officer and President of Refocus Group Inc., since October 28, 2013. Mr. Judy served as the Chief Commercialization Officer of Acufocus ...


Leadership Team

NamePositionTenureCompensationOwnership
J. Judy
CEO, President & Director6.5yrsno datano data
Zack Thompson
CFO & Senior VP of Business Development9yrsno datano data
Kevin Cady
Vice President of Marketing & Business Development5.25yrsno datano data
David Schanzlin
Chief Medical Officer8.17yrsno datano data
Martin Kaufman
Chief Regulatory Officer6.25yrsno datano data
Marga Wastalu
Director of Clinical Affairs6yrsno datano data

6.4yrs

Average Tenure

Experienced Management: RFCS's management team is seasoned and experienced (6.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
J. Judy
CEO, President & Director6.5yrsno datano data
Thomas Loarie
Chairman of the Board1.25yrsno datano data
Harry Jacobson
Director9.25yrsno datano data
Thomas Lyles
Director15.25yrsno datano data
Donald Phillips
Director3.25yrsno datano data

6.3yrs

Average Tenure

70yo

Average Age

Experienced Board: RFCS's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Top Shareholders

Company Information

Refocus Group, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Refocus Group, Inc.
  • Ticker: RFCS
  • Exchange: OTCPK
  • Founded: 1994
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$2.097m
  • Shares outstanding: 24.67m
  • Website: https://www.refocus-group.com

Location

  • Refocus Group, Inc.
  • 10210 North Central Expressway
  • Suite 400
  • Dallas
  • Texas
  • 75231
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RFCSOTCPK (Pink Sheets LLC)YesCommon StockUSUSDMar 2003

Biography

Refocus Group, Inc., a medical device company, engages in the research and development of treatments for human vision disorders, primarily for presbyopia. The company develops VisAbility Micro-Insert System, an investigational medical device that is in clinical trials for use in the binocular presbyopic treatment. It serves patients and eye care professionals. The company was founded in 1994 and is based in Dallas, Texas. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/01 11:53
End of Day Share Price2020/03/31 00:00
Earnings2005/09/30
Annual Earnings2004/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.